Word

BRC

Status

Pending

Status Code

681

Status Date

Tuesday, June 4, 2024

Serial Number

79340795

Mark Type

4

Filing Date

Friday, February 25, 2022

Published for Opposition

Tuesday, July 9, 2024

Trademark Owner History

Bicycletx Limited

Classifications

5 Pharmaceuticals, for use in the treatment and prevention of disease in the field of oncology for both solid and liquid tumours, for use in the treatment and prevention of metabolic disease, urology and renal disease, in the cardiovascular field, in the field of hematology, for use in the treatment and prevention of respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders; pharmaceutical products and preparations for use in the treatment and prevention of disease in the field of oncology; pharmaceutical products and preparations for use in the treatment and prevention of disease in the field of ophthalmology; pharmaceutical products and preparations for use in the treatment and prevention of disease in the field of neurology; anti-infective pharmaceutical products and preparations; pharmaceutical products and preparations for the treatment and/or prevention of respiratory disease; pharmaceutical products and preparations for the treatment and/or prevention of cardiovascular disease; pharmaceutical products and preparations for the treatment and/or prevention of metabolic disease; pharmaceutical products and preparations for the treatment and/or prevention of viral infections; pharmaceutical products and preparations for use in diagnostics and imaging, namely, clinical imaging agents; pharmaceutical products and preparations for the treatment and/or prevention of renal disease; pharmaceutical products and preparations for the treatment and/or prevention of gastrointestinal disease; pharmaceutical products and preparations for the treatment and/or prevention of muscular skeletal disease; none of the foregoing in the field of palliative care

44 Pharmaceutical compounding services; advisory services relating to pharmaceuticals; pharmaceutical consultation and providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; pharmaceutical compounding services in the field of oncology; pharmaceutical compounding services in the field of ophthalmology; pharmaceutical compounding services in the field of neurology; pharmaceutical compounding services in the field of anti-infectives; pharmaceutical compounding services in the field of respiratory disease; pharmaceutical compounding services in the field of cardiovascular disease; pharmaceutical compounding services in connection with metabolic disease; pharmaceutical compounding services in connection with the treatment and/or prevention of viral infections; pharmaceutical compounding services in connection with diagnostics and imaging; pharmaceutical compounding services in connection with renal disease; pharmaceutical compounding services in connection with gastrointestinal disease; pharmaceutical compounding services in connection with muscular skeletal disease; information, consultancy and advisory services relating to the aforesaid; none of the foregoing in the field of palliative care

42 Scientific and technological services and research and design relating thereto, namely, scientific research, new product design services, and new study design services in the fields of the development of future human and veterinary medical treatments in the field of oncology for both solid and liquid tumors, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders, diagnostic preparations and clinical imaging agents; industrial analysis and research services in the fields of oncology for both solid and liquid tumors, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders, diagnostic preparations and clinical imaging agents; pharmaceutical research and development services; medical research and development services; pharmaceutical testing and medical and scientific research, namely, conducting clinical trials for others; medical and scientific research, namely, conducting clinical trials for others; research and development in the field of oncology; research and development in the field of ophthalmology; research and development in the field of neurology; research and development in the field of anti-infective pharmaceuticals; research and development in the field of respiratory disease; research and development in the field of cardiovascular disease; research and development in the field of metabolic disease; research and development in the field of antiviral drugs; research and development in the field of diagnostics and imaging; research and development in the field of renal disease; research and development in the field of gastrointestinal disease; research and development in the field of muscular skeletal disease; information consultancy and advisory services relating to the aforesaid; none of the foregoing in the field of palliative care

Trademark Events

Sep 11, 2022

Non-Final Action (Ib Refusal) Prepared For Review

May 19, 2022

Sn Assigned For Sect 66a Appl From Ib

May 20, 2022

New Application Office Supplied Data Entered

May 24, 2022

Application Filing Receipt Mailed

Sep 7, 2022

Assigned To Examiner

Sep 10, 2022

Non-Final Action Written

Sep 24, 2022

Change Of Name/Address Rec'd From Ib

Oct 28, 2022

Refusal Processed By Mpu

Oct 28, 2022

Non-Final Action Mailed - Refusal Sent To Ib

Nov 21, 2022

Refusal Processed By Ib

Apr 26, 2023

Teas Response To Office Action Received

Apr 26, 2023

Correspondence Received In Law Office

Apr 26, 2023

Teas/Email Correspondence Entered

Oct 25, 2023

Notification Of Possible Opposition Sent To Ib

May 22, 2023

Suspension Letter Written

May 22, 2023

Letter Of Suspension E-Mailed

May 22, 2023

Notification Of Letter Of Suspension E-Mailed

Nov 12, 2023

Notification Of Possible Opposition - Processed By Ib

Dec 1, 2023

New Representative At Ib Received

Oct 25, 2023

Notification Of Possible Opposition Created, To Be Sent To Ib

Jan 8, 2024

Suspension Checked - To Attorney For Action

May 29, 2024

Teas/Email Correspondence Entered

May 29, 2024

Correspondence Received In Law Office

May 29, 2024

Teas Request For Reconsideration Received

Jan 29, 2024

Final Refusal Written

Jan 29, 2024

Final Refusal E-Mailed

Jan 29, 2024

Notification Of Final Refusal Emailed

Jun 1, 2024

Approved For Pub - Principal Register

Jun 19, 2024

Notification Of Notice Of Publication E-Mailed